KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Imaginant offers a unique measurement capability through its PELT coating thickness gauges
The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023
Health-tech startups have the potential to revolutionize the healthcare sector by supporting innovations
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
_256_384.jpg)
The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Subscribe To Our Newsletter & Stay Updated
